When was SAGE Therapeutics founded?

SAGE Therapeutics was founded in 1971 and raised its 1st funding round 40 years after it was founded.

Where is SAGE Therapeutics located?

SAGE Therapeutics is headquartered in Boston, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of SAGE Therapeutics?

Barry Greene of SAGE Therapeutics.

How many employees does SAGE Therapeutics have?

As of May 31, 2026, the latest employee count at SAGE Therapeutics is 198.

Is SAGE Therapeutics a funded company?

SAGE Therapeutics is a funded company, having raised a total of $106M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 2011.

How much is SAGE Therapeutics worth?

The last known valuation of SAGE Therapeutics was $***** as of Jun 16, 2025.

When was the latest funding round of SAGE Therapeutics?

SAGE Therapeutics' latest funding was a $***** Post IPO round on Jan 15, 2021, with participation from 0 investor.

Where does SAGE Therapeutics rank among its competitors?

SAGE Therapeutics ranks 57th amongst 4349 active competitors, of which 1025 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of SAGE Therapeutics?

SAGE Therapeutics' top competitors include Jazz Pharmaceuticals, Boston Scientific and Medtronic. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

SAGE Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drug candidates for the treatment of rare CNS disorders. The company is targeting GABAA receptors (inhibitory neurotransmitter receptors), and NMDA receptors (excitatory neurotransmitter receptors) and develops a pipeline of products fo broad spectrum of disorders, including disorders of mood, seizure, cognition, anxiety, sleep, pain, epilepsy, and movement. Its product candidate, SAGE-547, is for postpartum depression.

Website: sagerx.com
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

1971

Location

Boston, United States

Stage

Acquired

Total Funding

$106M in 6 rounds

Latest Funding Round

Post IPO, Jan 15, 2021, $*****

Last Known Valuation

$***** as on Jun 16, 2025

Investors

Orbimed & 11 more

Ranked

57^th among 4349 active competitors

Employee Count

198 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 538 more

Exit Details

Acquired by Supernus Pharmaceuticals (Jun 16, 2025)

View SAGE Therapeutics' full profile

SAGE Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Sage Therapeutics, Inc. CIN: 209946995 , United States, Active	Mar 27, 2023	-	-	-
Sage Therapeutics, Inc CIN: 27-4486580 , United States, Active	Dec 31, 2010	-	487 (As on Feb 29, 2024)	-
Sage Therapeutics CIN: 274486580 , United States, Active	Dec 31, 1999	-	352 (As on Dec 31, 2024)	-

SAGE Therapeutics got acquired by Supernus Pharmaceuticals on Jun 16, 2025 at an acquisition amount of $*****.

Click here to take a look at SAGE Therapeutics's acquisition in detail

SAGE Therapeutics has raised a total funding of $106M over 6 rounds. Its first funding round was on Sep 2011. SAGE Therapeutics has 12 institutional investors.

Here is the list of recent funding rounds of SAGE Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 15, 2021	4322996	Post IPO	3695496	6727917	6892957	2856790
Mar 14, 2014	2802002	Series C	5907502	8924715	4749935	Third Rock Ventures & 1 more
Jan 21, 2014	4384745	Series C	2437136	4311104	8997989	2566252

Access funding benchmarks and valuations. Sign up today!

View details of SAGE Therapeutics's funding rounds and investors

SAGE Therapeutics' employee count trend

SAGE Therapeutics has 198 employees as of May 26. Here is SAGE Therapeutics's employee count trend over the years:

Employee count trend for SAGE Therapeutics

Uncover SAGE Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SAGE Therapeutics include Jazz Pharmaceuticals, Boston Scientific and Medtronic. Here is the list of Top 10 competitors of SAGE Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Boston Scientific 1979, Marlborough (United States), Public	Wide range of medical devices	-	JANA Partners, Barclays & 8 others	81/100
3rd	Medtronic 1949, Minneapolis (United States), Public	Developer of medical equipment for chronic diseases	-	Greyrock Investments, Saints Capital & 23 others	79/100
4th	Fujifilm 1934, Germany, Acquired	Developer of healthcare, electronics, and imaging solutions for various applications	-	ENEOS Group, BOM & 3 others	77/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Omega Funds & 17 others	75/100
6th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, Bezos Expeditions & 14 others	74/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
8th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
9th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
10th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	72/100
57th	SAGE Therapeutics 1971, Boston (United States), Acquired	Developer of drug candidates for the treatment of rare CNS disorders	$106M	BB Biotech, Deutsche Bank & 10 others	66/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on SAGE Therapeutics's competitors? Click here to see the top ones

SAGE Therapeutics has made no investments or acquisitions yet.

Here is the latest report on SAGE Therapeutics's sector:

Free

Diversified Medical Devices - Sector Report

Edition: October, 2025 (55 Pages)

View all reports related to SAGE Therapeutics

Media has covered SAGE Therapeutics for a total of 25 events in the last 1 year, 5 of them have been about company updates and 1 about people movement.